This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SAPPHIRE Worldwide Study Data Presented At TCT 2012

Cordis Corporation today announced the presentation of the SAPPHIRE study results for the first 15,000 patients at the TCT 2012 conference in Miami.

SAPPHIRE ( STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH- RISK FOR ENDARTERECTOMY) World Wide (SWW) Registry is one of the largest carotid artery stenting (CAS) studies to date with more than 15,000 patients undergoing CAS with cerebral protection. It is a multicenter, prospective study to evaluate the outcomes of CAS using the PRECISE® Nitinol Stent and ANGIOGUARD® XP/RX Emboli Capture Guidewire System in the treatment of obstructive carotid artery disease. The peri-procedural results were presented by Christopher Metzger, MD, National Co-Principal Investigator of the study.

“Cordis is committed to providing clinically relevant data on the optimal treatment strategies for carotid revascularization,” said Shlomi Nachman, Worldwide President, Cordis Corporation. “We are pleased with the results of SAPPHIRE and look forward to additional data as more patients are enrolled.”

Enrollment began October, 2006 and is ongoing. Data were reported on 15,003 patients, of whom 4,569 (30%) were symptomatic and 10,433 (70%) were asymptomatic. Overall, the MAE rate at 30 days was 4.5% (death 1.2%, MI 0.6%, stroke 3.3%). There was a significant difference in the combined rate of stroke or death at 30 days between symptomatic (5.6%) and asymptomatic (3.5%) patients (p<0.0001), and patients 75 years of age and older (5.6%) compared to younger (2.9%) patients (p<0.0001).

“We are pleased with the results which continue to demonstrate favorable clinical outcomes for carotid stenting consistent with earlier findings in this study at previous lower sample sizes,” said Hans-Peter Stoll, MD, Vice President World-Wide Clinical Research & Medical Affairs, Cordis Corporation. “This data compares favorably to other reports of CAS in a high-surgical risk population and is similar to results reported in the CREST trial comparing CAS to surgery in a non-high surgical risk population.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs